← Back to Search

Tyrosine Kinase Inhibitor

Crizotinib for Cancer with ROS1 Genetic Changes

Phase 2

Waitlist Available

Led By Aaron S Mansfield

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block)

Patients must be positive for translocation or inversion events involving the ROS1 gene via the MATCH Master Protocol

Timeline

Screening 3 weeks

Treatment Varies

Follow Up assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Awards & highlights

Study Summary

This trial is testing if crizotinib can shrink or stop the growth of cancer that has a genetic change called ROS1 translocation.

Who is the study for?

This trial is for cancer patients with a specific genetic change called ROS1 translocation, excluding those with non-small cell lung cancer (NSCLC) or a history of lung disease. Participants must have normal heart rhythms and not be allergic to crizotinib or similar compounds. They can't use certain drugs that affect crizotinib's metabolism and shouldn't have used any ROS1 inhibitors before.Check my eligibility

What is being tested?

The study tests Crizotinib, which may inhibit the growth of cancers by blocking the protein ROS1. It's for patients whose cancers are identified to have this targetable genetic alteration. The goal is to see if Crizotinib can shrink these cancers or halt their progression.See study design

What are the potential side effects?

Crizotinib might cause side effects like vision problems, nausea, diarrhea, liver issues, heart problems including abnormal rhythms, swelling in lungs leading to difficulty breathing (pneumonitis), and blood test abnormalities.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My recent ECG showed no significant heart issues.

Select...

My cancer has a specific genetic change in the ROS1 gene.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration

This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Objective Response Rate (ORR)

Secondary outcome measures

6-month Progression-free Survival (PFS) Rate

Progression Free Survival (PFS)

Side effects data

From 2020 Phase 3 trial • 207 Patients • NCT01639001

66%

Alanine aminotransferase increased

61%

Diarrhoea

60%

Aspartate aminotransferase increased

59%

Vomiting

54%

Nausea

41%

White blood cell count decreased

40%

Visual impairment

38%

Neutrophil count decreased

36%

Constipation

32%

Cough

28%

Headache

27%

Dizziness

26%

Oedema peripheral

26%

Decreased appetite

25%

Blood albumin decreased

21%

Pain in extremity

21%

Nasopharyngitis

20%

Neutropenia

19%

Anaemia

18%

Pyrexia

18%

Hypoalbuminaemia

17%

Upper respiratory tract infection

15%

Chest pain

15%

Dyspnoea

14%

Disease progression

14%

Blood lactate dehydrogenase increased

13%

Blood creatine phosphokinase increased

13%

Sinus bradycardia

13%

Vision blurred

13%

Gamma-glutamyltransferase increased

13%

Back pain

13%

Insomnia

13%

Protein total decreased

13%

Hypocalcaemia

12%

Leukopenia

12%

Rash

12%

Hypokalaemia

11%

Abdominal distension

10%

Abdominal pain

10%

Blood alkaline phosphatase increased

10%

Pain

10%

Alopecia

Chest discomfort

Blood creatinine increased

Fatigue

Oedema

Hypoaesthesia

Lymphocyte count decreased

Arthralgia

Asthenia

Abdominal pain upper

Platelet count decreased

Hypertension

Haemoptysis

Face oedema

Photopsia

Toothache

Haemoglobin decreased

Paraesthesia

Muscular weakness

Bradycardia

Taste disorder

Blood creatine phosphokinase MB increased

Pneumonia

Hyponatraemia

Hypoproteinaemia

Musculoskeletal pain

Red blood cell count decreased

Productive cough

Blood bilirubin increased

Pruritus

Thrombocytopenia

Pulmonary embolism

Dysphagia

Pleural effusion

Death

Interstitial lung disease

Pneumothorax

Hepatic function abnormal

Anaphylactic shock

Phlebitis

Intestinal obstruction

Abdominal discomfort

Subcutaneous emphysema

Impaired healing

Pancreatitis

Pancreatitis acute

Drug-induced liver injury

Gastrointestinal viral infection

Lower respiratory tract infection

Goitre

Ocular hypertension

Post procedural infection

Deep vein thrombosis

Cellulitis

Hyperuricaemia

Colon adenoma

Adenomyosis

Circulatory collapse

Fracture

Altered state of consciousness

100%

80%

60%

40%

20%

Study treatment Arm

Crizotinib

Chemotherapy

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (crizotinib)Experimental Treatment1 Intervention

Patients receive crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Crizotinib

2014

Completed Phase 3

~2370

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor

13,657 Previous Clinical Trials

40,933,663 Total Patients Enrolled

Aaron S MansfieldPrincipal InvestigatorECOG-ACRIN Cancer Research Group

3 Previous Clinical Trials

162 Total Patients Enrolled

Media Library

Crizotinib (Tyrosine Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04439253 — Phase 2

Cancer Research Study Groups: Treatment (crizotinib)

Cancer Clinical Trial 2023: Crizotinib Highlights & Side Effects. Trial Name: NCT04439253 — Phase 2

Crizotinib (Tyrosine Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04439253 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any openings to become a participant in this experiment?

"Unfortunately, this clinical trial is not actively recruiting participants. The study was initially posted on August 12th 2015 and the last update occurred on August 30th 2022. Nevertheless, there are currently 4739 other studies searching for volunteers at this time."

Answered by AI

How many participants are currently involved in this research endeavor?

"This research is no longer looking for enrollees. The investigation was initially posted on August 12, 2015 and the last update happened on 8/30/2022. If you look into other studies, there are 4669 trials searching for patients with refractory plasma cell myeloma and 70 clinical investigations actively enrolling people in Crizotinib therapy."

Answered by AI

What objective is this experiment aiming to achieve?

"This study's primary aim is to evaluate the Objective Response Rate (ORR) through assessing Tumours at baseline, every 2 cycles for 26 rounds of analysis and every 3 cycles until disease progression or up to 3 years post registration. Secondary outcomes include 6-month Progression-free Survival (PFS) Rate estimated with Kaplan-Meier method, Overall survival (OS), evaluated specifically for each drug using the same statistical approach and PFS assessed via a similar technique."

Answered by AI

Has Crizotinib received regulatory authorization from the Food and Drug Administration?

"Crizotinib's safety has been partially established by clinical data, thus it received a rating of 2. This Phase 2 trial does not yet have any information confirming efficacy."

Answered by AI

What health conditions does Crizotinib typically address?

"Crizotinib is commonly prescribed to alleviate the effects of renal dysfunction, amino acid supplementation and a variety of other medical issues."

Answered by AI

Is this pioneering clinical trial breaking new ground?

"To date, 70 clinical trials for Crizotinib have been launched in 1216 cities from 37 countries. This drug first appeared in a 2007 Baxter Healthcare Corporation-sponsored study that included 4640 participants and concluded with Phase 4 approval. Over the last 14 years, 79 studies involving this medication have been conducted."

Answered by AI

Recent research and studies

npj Precision OncologyJournal

Crizotinib in Patients with Tumors Harboring ALK or ROS1 Rearrangements in the NCI-MATCH Trial

Mansfield, A. S., Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, et al.. 2022. “Crizotinib in Patients with Tumors Harboring ALK or ROS1 Rearrangements in the NCI-MATCH Trial”. Npj Precision Oncology. Springer Science and Business Media LLC. doi:10.1038/s41698-022-00256-w.

clinicaltrials.govStudy

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

2015. "Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04439253.